X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (5774) 5774
Book Review (651) 651
Publication (304) 304
Conference Proceeding (33) 33
Book Chapter (27) 27
Dissertation (8) 8
Magazine Article (1) 1
Newspaper Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (5015) 5015
humans (3477) 3477
animals (2284) 2284
male (2116) 2116
neprilysin (1879) 1879
neprilysin - metabolism (1585) 1585
female (1531) 1531
neprilysin - antagonists & inhibitors (1240) 1240
middle aged (954) 954
rats (929) 929
adult (871) 871
aged (765) 765
neutral endopeptidase (755) 755
immunohistochemistry (703) 703
mice (660) 660
neprilysin - analysis (599) 599
pathology (594) 594
pharmacology & pharmacy (559) 559
abridged index medicus (527) 527
biochemistry & molecular biology (518) 518
neprilysin - genetics (517) 517
expression (503) 503
heart failure (484) 484
cardiac & cardiovascular systems (467) 467
neurosciences (435) 435
cd10 (402) 402
alzheimer's disease (384) 384
angiotensin-converting enzyme (349) 349
aged, 80 and over (341) 341
oncology (337) 337
molecular sequence data (322) 322
protease inhibitors - pharmacology (320) 320
amino acid sequence (316) 316
prognosis (315) 315
heart failure - drug therapy (300) 300
cell biology (294) 294
enkephalinase (292) 292
brain (288) 288
adolescent (282) 282
enzymes (282) 282
amyloid beta-peptides - metabolism (281) 281
hematology (280) 280
neprilysin - biosynthesis (278) 278
antigens, neoplasm - analysis (270) 270
child (263) 263
peptides (263) 263
glycopeptides - pharmacology (262) 262
blood pressure - drug effects (261) 261
hypertension (258) 258
flow cytometry (253) 253
diagnosis, differential (252) 252
alzheimers-disease (245) 245
cells, cultured (244) 244
angiotensin-converting enzyme inhibitors - pharmacology (242) 242
analysis (241) 241
substance-p (240) 240
dose-response relationship, drug (239) 239
heart-failure (238) 238
kinetics (235) 235
neprilysin - physiology (235) 235
in vitro techniques (231) 231
research (225) 225
angiotensin (220) 220
biomarkers, tumor - analysis (219) 219
disease models, animal (219) 219
immunophenotyping (218) 218
time factors (217) 217
cells (216) 216
rats, sprague-dawley (214) 214
phenotype (213) 213
natriuretic peptides (211) 211
a-beta (209) 209
thiorphan - pharmacology (209) 209
endopeptidases - metabolism (206) 206
gene expression (206) 206
enalapril (205) 205
peripheral vascular disease (205) 205
hydrolysis (204) 204
medicine, research & experimental (202) 202
peptidyl-dipeptidase a - metabolism (202) 202
peptide (197) 197
physiology (195) 195
neprilysin inhibition (192) 192
treatment outcome (192) 192
child, preschool (182) 182
cell line (177) 177
heart failure - physiopathology (176) 176
diagnosis (174) 174
lcz696 (172) 172
rats, wistar (172) 172
tetrazoles - therapeutic use (172) 172
brain - metabolism (171) 171
inhibition (171) 171
kidney (171) 171
cancer (169) 169
alzheimer disease - metabolism (166) 166
substrate specificity (166) 166
brain - enzymology (165) 165
aminobutyrates - therapeutic use (164) 164
proteins (164) 164
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5439) 5439
Chinese (111) 111
Japanese (57) 57
Russian (54) 54
French (49) 49
German (39) 39
Polish (17) 17
Spanish (11) 11
Italian (7) 7
Czech (6) 6
Korean (5) 5
Portuguese (4) 4
Croatian (2) 2
Hungarian (2) 2
Romanian (2) 2
Serbian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Circulation, ISSN 0009-7322, 2015, Volume 131, Issue 1, pp. 54 - 61
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 2/2012, Volume 109, Issue 9, pp. 3510 - 3515
A 30-d course of oral administration of a semipurif ied extract of the root of Withania somnifera consisting predominantly of withanolides and withanosides... 
Oligomers | Anger | Pathology | Brain | Messenger RNA | Liver | Medical treatment | LDL lipoproteins | Amyloids | Alzheimers disease | Herbal extract | Neurodegenerative disease | Dementia | CLEARANCE | neurodegenerative disease | MEMORY | MULTIDISCIPLINARY SCIENCES | herbal extract | AMYLOID-BETA-PEPTIDE | dementia | BLOOD-BRAIN-BARRIER | SYNAPTIC PLASTICITY | STRATEGIES | Up-Regulation | Liver - pathology | Male | Low Density Lipoprotein Receptor-Related Protein-1 - physiology | Low Density Lipoprotein Receptor-Related Protein-1 - genetics | Neprilysin - biosynthesis | Amyloid beta-Peptides - blood | Alzheimer Disease - pathology | Brain - metabolism | Liver - drug effects | Microglia - pathology | Neprilysin - genetics | Phytotherapy | Drug Evaluation, Preclinical | Neprilysin - physiology | Disease Models, Animal | Oligonucleotides, Antisense - pharmacology | Microglia - drug effects | Plaque, Amyloid - pathology | Administration, Oral | Liver - metabolism | Alzheimer Disease - drug therapy | Presenilin-1 - genetics | Mice, Transgenic | Plant Extracts - isolation & purification | Low Density Lipoprotein Receptor-Related Protein-1 - biosynthesis | Maze Learning - drug effects | Organ Specificity | Brain - drug effects | Amyloid beta-Protein Precursor - genetics | Animals | Plant Roots - chemistry | Brain - pathology | Mice | Plant Extracts - therapeutic use | Alzheimer Disease - blood | Withania - chemistry | Prevention | Physiological aspects | Alzheimer's disease | Health aspects | Low density lipoproteins | Flowers & plants | Peptides | Low density lipoprotein | Rodents | Animal models | Neurodegenerative diseases | Proteinase | Roots | Oral administration | Transgenic mice | beta -Amyloid | Amyloid precursor protein | Monomers | Lipoproteins | Presenilin 1 | Models | Neprilysin | Plaques | Index Medicus | Biological Sciences
Journal Article
Circulation, ISSN 0009-7322, 06/2016, Volume 133, Issue 23, pp. 2254 - 2262
BACKGROUND—Many episodes of worsening of heart failure (HF) are treated by increasing oral therapy or temporary intravenous treatment in the community or... 
mortality | heart failure | hospitalization | neprilysin | emergency service, hospital | sacubitril/valsartan | NEPRILYSIN INHIBITION | CARDIAC & CARDIOVASCULAR SYSTEMS | RISK | CARE | SUBSEQUENT MORTALITY | HOSPITAL READMISSION | EMERGENCY-DEPARTMENT | THERAPY | PERIPHERAL VASCULAR DISEASE | OUTCOMES | ENALAPRIL | INPATIENT | Angiotensin II Type 1 Receptor Blockers - adverse effects | Prospective Studies | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Humans | Middle Aged | Heart Failure - physiopathology | Aminobutyrates - adverse effects | Male | Aminobutyrates - therapeutic use | Enalapril - therapeutic use | Enalapril - adverse effects | Heart Failure - therapy | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Time Factors | Angiotensin-Converting Enzyme Inhibitors - adverse effects | Endpoint Determination | Protease Inhibitors - adverse effects | Female | Heart Failure - diagnosis | Protease Inhibitors - therapeutic use | Heart Failure - mortality | Double-Blind Method | Risk Assessment | Risk Factors | Treatment Outcome | Hospitalization | Neprilysin - metabolism | Ambulatory Care | Disease Progression | Neprilysin - antagonists & inhibitors | Tetrazoles - therapeutic use | Aged | Tetrazoles - adverse effects | Research Design | Heart failure | Care and treatment | Emergency service | Receptors | Hospitals | Analysis | Angiotensin | Comparative analysis | ACE inhibitors | Health aspects | Risk factors | Index Medicus | Abridged Index Medicus | hospital readmission | emergency-department | enalapril | inpatient | therapy | subsequent mortality | Kardiologi | Cardiac and Cardiovascular Systems | neprilysin inhibition | Cardiovascular System & Cardiology | outcomes | emergency service | risk | hospital | care
Journal Article
Journal of Cardiovascular Pharmacology, ISSN 0160-2446, 06/2017, Volume 69, Issue 6, pp. 374 - 381
We compared the systolic blood pressure (SBP)-lowering efficacy and safety of crystalline valsartan/sacubitril (LCZ696, an angiotensin receptor... 
Systolic hypertension | Angiotensin receptor blocker | Angiotensin receptor-neprilysin inhibitor | Valsartan | Sacubitril | Neprilysin inhibitor | systolic hypertension | CARDIAC & CARDIOVASCULAR SYSTEMS | NATRIURETIC PEPTIDES | angiotensin receptor blocker | angiotensin receptor-neprilysin inhibitor | BLOOD-PRESSURE | HEMODYNAMICS | RECEPTOR-NEPRILYSIN INHIBITOR | neprilysin inhibitor | valsartan | PHARMACOLOGY & PHARMACY | sacubitril | AGE | Valsartan - administration & dosage | Angiotensin II Type 1 Receptor Blockers - adverse effects | Humans | Middle Aged | Aminobutyrates - adverse effects | Antihypertensive Agents - administration & dosage | Hypertension - drug therapy | Male | Systole | North America | Time Factors | Tetrazoles - administration & dosage | Protease Inhibitors - administration & dosage | Protease Inhibitors - adverse effects | Female | Blood Pressure - drug effects | Aminobutyrates - administration & dosage | Hypertension - diagnosis | Republic of Korea | Angiotensin II Type 1 Receptor Blockers - administration & dosage | Argentina | Double-Blind Method | Europe | Valsartan - adverse effects | Treatment Outcome | Neprilysin - metabolism | Hypertension - physiopathology | Antihypertensive Agents - adverse effects | India | Neprilysin - antagonists & inhibitors | Aged | Tetrazoles - adverse effects | Index Medicus
Journal Article
European Journal of Heart Failure, ISSN 1388-9842, 2013, Volume 15, Issue 9, pp. 1062 - 1073
Journal Article